Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection.

"Despite high-grade exposures without masks, all diagnostic tests in all participants who took Mito-MES within 72 h (n = 26) were negative (Fig. 300077-X/fulltext#fig3)) showing that none of the study participants developed SARS-CoV-2 infection. Two out of 14 participants (14.3%) who took Mito-MES within 3–5 days post exposure also had at least 4 negative COVID-19 diagnostic tests (Fig. 400077-X/fulltext#fig4)). Thirty (75.0%) out of 40 study participants in the control group who had high-grade exposures to SARS-CoV-2 without masks, developed confirmed SARS-CoV-2 infection (Fig. 500077-X/fulltext#fig5))."

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00077-X/fulltext00077-X/fulltext)

Review - (Published: 04 December 2024) - Mitochondrial dysfunction in acute and post-acute phases of COVID-19 and risk of non-communicable diseases : https://www.nature.com/articles/s44324-024-00038-x